Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 13/20 | 0.72 |
| ▸ | RAB9A | P51151 | 13/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.72 |
| ▸ | MEN1 | O00255 | 5/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.72 |
| ▸ | MAPT | P10636 | 4/20 | 0.72 |
| ▸ | HTT | P42858 | 3/20 | 0.72 |
| ▸ | POLB | P06746 | 3/20 | 0.72 |
| ▸ | TP53 | P04637 | 3/20 | 0.72 |
| ▸ | USP2 | O75604 | 1/20 | 0.72 |
| ▸ | SCD | O00767 | 7/20 | 0.69 |
| ▸ | PKM | P14618 | 3/20 | 0.62 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.62 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.62 |
| ▸ | CASP2 | P42575 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12199325 | 1.00 | NPC1 (0.72) | NPC1RAB9AKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL12199348 | 1.00 | NPC1 (0.72) | NPC1RAB9AKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL2484180 | 0.86 | NPC1 (0.74) | NPC1RAB9AKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL12199326 | 0.86 | NPC1 (0.74) | NPC1RAB9AKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL12199351 | 0.86 | NPC1 (0.74) | NPC1RAB9AKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL12199334 | 0.85 | NPC1 (0.73) | NPC1RAB9AKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL12199356 | 0.85 | NPC1 (0.73) | NPC1RAB9AKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL13329426 | 0.85 | NPC1 (0.73) | NPC1RAB9AKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL13329388 | 0.84 | NPC1 (0.67) | NPC1RAB9AKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL12199340 | 0.84 | NPC1 (0.67) | NPC1RAB9AKMT2AMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376463-A1 | BENZOTHIAZOLE AMIDES FOR DETECTION OF AMYLOID BETA | Bayer Pharma Aktiengesellschaft (DE) | 2011-10-19 | — | — | EP | disclosed |
| US-20110243846-A1 | BENZOTHIAZOLE AMIDES FOR DETECTION OF AMYLOID BETA | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-10-06 | — | — | US | disclosed |
| US-20110243846-A1 | BENZOTHIAZOLE AMIDES FOR DETECTION OF AMYLOID BETA | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-10-06 | — | — | US | disclosed |
| US-20110243846-A1 | BENZOTHIAZOLE AMIDES FOR DETECTION OF AMYLOID BETA | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-10-06 | — | — | US | disclosed |
| WO-2010066357-A1 | BENZOTHIAZOLE AMIDES FOR DETECTION OF AMYLOID BETA | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010066357-A1 | BENZOTHIAZOLE AMIDES FOR DETECTION OF AMYLOID BETA | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110243846-A1 | BENZOTHIAZOLE AMIDES FOR DETECTION OF AMYLOID BETA | APP, APBA1, BACE1 | NPC1 473/4885RAB9A 2966/4885KMT2A 2763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.